Gleason Group, Inc. Cue Biopharma, Inc. Transaction History
Gleason Group, Inc.
- $546 Million
- Q3 2024
A detailed history of Gleason Group, Inc. transactions in Cue Biopharma, Inc. stock. As of the latest transaction made, Gleason Group, Inc. holds 6,000 shares of CUE stock, worth $6,180. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,000
Previous 6,000
-0.0%
Holding current value
$6,180
Previous $7,000
42.86%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding CUE
# of Institutions
52Shares Held
14.1MCall Options Held
14.4KPut Options Held
2.6K-
Bleichroeder LP New York, NY5MShares$5.15 Million1.28% of portfolio
-
Slate Path Capital LP New York, NY2.4MShares$2.47 Million0.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.03MShares$2.09 Million0.0% of portfolio
-
Black Rock Inc. New York, NY757KShares$779,4380.0% of portfolio
-
Geode Capital Management, LLC Boston, MA509KShares$524,0910.0% of portfolio
About Cue Biopharma, Inc.
- Ticker CUE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,381,700
- Market Cap $36.4M
- Description
- Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...